The EU Biotech Act introduces both political ambition and significant legal uncertainty, with key questions remaining around its scope and implementation. This roundtable will examine the practical challenges, transitional ambiguity and strategic opportunities arising from the new legislation and assess how biotech companies can leverage the Act to reposition their competitive footprint in Europe.
Agenda Track No.:
Track 3
Session Type:
General Session (Presentation)
Force Inline Description:
0